Founded Year

2017

Stage

Series B | Alive

Total Raised

$75.9M

Last Raised

$64M | 10 mos ago

About Quit Genius

Quit Genius has created a gamified behavioral therapy app to help smokers quit smoking.

Quit Genius Headquarter Location

1732 1st Ave #20163

New York, New York, 10128,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Quit Genius's Products & Differentiation

See Quit Genius's products and how their products differentiate from alternatives and competitors

  • Tobacco Cessation

    Technology, medication and clinical professionals to treat members with smoking and vaping addiction.

    Differentiation

    % quit rates 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Quit Genius

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Quit Genius is included in 5 Expert Collections, including Digital Health.

D

Digital Health

13,210 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health Tech

1,170 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

C

Conference Exhibitors

5,302 items

T

Telehealth

2,800 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

D

Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.

Latest Quit Genius News

Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis

May 20, 2022

The solution uses gamification to increase patient adherence. Credit: Sidekick Health Digital therapeutics firm, Sidekick Health has joined forces with pharma giant Pfizer to launch an integrated digital therapeutics solution for Atopic Dermatitis (AD). The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later this year. This marks the next phase of a growing collaboration between Sidekick and Pfizer  to develop digital patient support programmes globally, including expansion into 24 markets by 2024. WHY IT MATTERS AD is an inflammatory, pruritic, chronic, or chronically relapsing skin disease that affects up to 14% of adults worldwide. People living with moderate to severe AD often suffer from constant and relentless itching, leading to sleep deprivation, increased stress and anxiety that affects the quality of their lives. However, one of the challenges of effectively treating AD is that patients’ adherence to treatment tends to be low. Sidekick’s digital therapeutics platform aims to address this using gamification principles and behavioural economics to deliver treatment through care pathways that help inspire lasting behavioural change. This positively impacts health outcomes by addressing the same endpoints as traditional treatments. Sidekick recently completed an independently funded feasibility study for AD, showing a reduction in skin lesion severity and extension by more than 40%, as evaluated by dermatologists, and close to 50% reduction in the overall severity of symptoms. People who participated in the study also reported a significant improvement in health-related quality of life and increased adherence to treatments and preventive measures. THE LARGER CONTEXT Earlier this month, Sidekick announced the closing of a $55 million (€52M) Series B round  which brings its total funding in less than two years to $75 million (€70.8M). As well as partnering with Pfizer, the firm has previously worked with global pharma firm Bayer , to develop integrated combination therapeutics. ON THE RECORD Dr Tryggvi Thorgeirsson, CEO and cofounder, Sidekick, said: “We are extremely excited to be entering the next phase in our ongoing relationship with Pfizer. At Sidekick, it’s always been our ambition to help as many people as possible to make long-lasting improvements to their disease management, with the aim of improving people’s health outcomes and quality of life. Our work with Pfizer escalates our mission to bring digital therapeutics into the homes of people around the world.” Ana Paula Carvalho, regional president, international developed markets, inflammation and immunology, Pfizer, said: “Autoimmune and chronic inflammatory diseases such as atopic dermatitis can be debilitating, disfiguring, and distressing, dramatically affecting what people living with the disease can do. “At Pfizer, we recognize patient care goes beyond medical advances and we are proud to be working with Sidekick to put their technology in the hands of people who need it most. A holistic approach to treating the individual, not just the disease, is essential in order to advance the standard of care for patients and to empower them to live their best lives.” Tags:

Quit Genius Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Quit Genius Rank

  • When was Quit Genius founded?

    Quit Genius was founded in 2017.

  • Where is Quit Genius's headquarters?

    Quit Genius's headquarters is located at 1732 1st Ave, New York.

  • What is Quit Genius's latest funding round?

    Quit Genius's latest funding round is Series B.

  • How much did Quit Genius raise?

    Quit Genius raised a total of $75.9M.

  • Who are Quit Genius's competitors?

    Competitors of Quit Genius include Pear Therapeutics and 7 more.

  • What products does Quit Genius offer?

    Quit Genius's products include Tobacco Cessation and 2 more.

You May Also Like

Lionrock Logo
Lionrock

Lionrock provides treatment online for alcohol abuse, drug addiction, and other substance use disorders by secure video conference.

Click Therapeutics Logo
Click Therapeutics

Click Therapeutics develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. Click's smoking cessation program is currently available nationwide through a variety of payers, providers, and employers. Click Therapeutics was founded in 2012 and is based in New York, New York.

Pivot Logo
Pivot

Pivot is a digital health company on a mission to use mobile technology, behavioral science, and clinical expertise to engage and empower. The company's Pivot combines wearable tech, clinical expertise, personal coaching, and behavioral science to help people quit smoking.

Eleanor Health Logo
Eleanor Health

Eleanor Health provides evidence-based, whole-person care specializing in addressing the unique complexities of individuals and populations with substance use disorders and mental health needs. Eleanor leverages proprietary technology and data-driven insights, compassionate teams, and population- and value-based payments to deliver clinical and financial outcomes. Eleanor Health was founded in 2019 and is based in Waltham, Massachusetts.

A
Amalgam Rx

Amalgam Rx creates custom, digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management.

G
Groups

Groups treats opiate addiction with group therapy and Suboxone. Groups' treatment model is affordable and proven to deliver results, with an approach that is grounded in community, accountability, and the belief everyone can live substance-free.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.